"Weight Loss" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Decrease in existing BODY WEIGHT.
| Descriptor ID |
D015431
|
| MeSH Number(s) |
C23.888.144.243.963 G07.345.249.314.120.200.963
|
| Concept/Terms |
Weight Loss- Weight Loss
- Loss, Weight
- Losses, Weight
- Weight Losses
- Weight Reduction
- Reduction, Weight
- Reductions, Weight
- Weight Reductions
|
Below are MeSH descriptors whose meaning is more general than "Weight Loss".
Below are MeSH descriptors whose meaning is more specific than "Weight Loss".
This graph shows the total number of publications written about "Weight Loss" by people in this website by year, and whether "Weight Loss" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 1 | 1 | 2 |
| 2000 | 2 | 0 | 2 |
| 2001 | 0 | 1 | 1 |
| 2002 | 2 | 4 | 6 |
| 2003 | 1 | 4 | 5 |
| 2004 | 3 | 4 | 7 |
| 2005 | 4 | 6 | 10 |
| 2006 | 6 | 4 | 10 |
| 2007 | 5 | 3 | 8 |
| 2008 | 3 | 7 | 10 |
| 2009 | 4 | 9 | 13 |
| 2010 | 7 | 8 | 15 |
| 2011 | 5 | 9 | 14 |
| 2012 | 6 | 4 | 10 |
| 2013 | 8 | 7 | 15 |
| 2014 | 7 | 8 | 15 |
| 2015 | 9 | 9 | 18 |
| 2016 | 12 | 8 | 20 |
| 2017 | 9 | 10 | 19 |
| 2018 | 6 | 3 | 9 |
| 2019 | 4 | 5 | 9 |
| 2020 | 3 | 5 | 8 |
| 2021 | 6 | 2 | 8 |
| 2022 | 1 | 10 | 11 |
To return to the timeline,
click here.
Below are the most recent publications written about "Weight Loss" by people in Profiles.
-
Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to -5 studies. Diabetes Obes Metab. 2023 04; 25(4):965-974.
-
Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses. Diabetes Obes Metab. 2023 02; 25(2):468-478.
-
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022 10; 28(10):2083-2091.
-
Long-term maintenance of weight loss. Lancet Public Health. 2022 10; 7(10):e806-e807.
-
Single Versus Double Anastomosis Duodenal Switch in the Management of Obesity: A Meta-analysis and Systematic Review. Surg Laparosc Endosc Percutan Tech. 2022 10 01; 32(5):595-605.
-
Pharmacologic Weight Management in the Era of Adolescent Obesity. J Clin Endocrinol Metab. 2022 09 28; 107(10):2716-2728.
-
Examining the evidence for weight management in individuals with type 2 diabetes. Diabetes Obes Metab. 2022 08; 24(8):1411-1422.
-
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022 May; 28(5):528-562.
-
New Horizons. A New Paradigm for Treating to Target with Second-Generation Obesity Medications. J Clin Endocrinol Metab. 2022 03 24; 107(4):e1339-e1347.
-
JCL Roundtable. Obesity, Diabetes, and Liver Disease in Relation to Cardiovascular Risk. J Clin Lipidol. 2022 Mar-Apr; 16(2):115-127.